title: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
abstract: BACKGROUND
  The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known.
  
  
  METHODS
  We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving 4360 patients. The patients were treated for a median of 4.0 years. The primary outcome was the time to monotherapy failure, which was defined as a confirmed level of fasting plasma glucose of more than 180 mg per deciliter (10.0 mmol per liter), for rosiglitazone, as compared with metformin or glyburide. Prespecified secondary outcomes were levels of fasting plasma glucose and glycated hemoglobin, insulin sensitivity, and beta-cell function.
  
  
  RESULTS
  Kaplan-Meier analysis showed a cumulative incidence of monotherapy failure at 5 years of 15% with rosiglitazone, 21% with metformin, and 34% with glyburide. This represents a risk reduction of 32% for rosiglitazone, as compared with metformin, and 63%, as compared with glyburide (P<0.001 for both comparisons). The difference in the durability of the treatment effect was greater between rosiglitazone and glyburide than between rosiglitazone and metformin. Glyburide was associated with a lower risk of cardiovascular events (including congestive heart failure) than was rosiglitazone (P<0.05), and the risk associated with metformin was similar to that with rosiglitazone. Rosiglitazone was associated with more weight gain and edema than either metformin or glyburide but with fewer gastrointestinal events than metformin and with less hypoglycemia than glyburide (P<0.001 for all comparisons).
  
  
  CONCLUSIONS
  The potential risks and benefits, the profile of adverse events, and the costs of these three drugs should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00279045 [ClinicalTrials.gov].).
authors.affiliation: Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle 98108, USA. skahn@u.washington.edu
authors.forename: Steven E
authors.initials: SE
authors.lastname: Kahn
authors.forename: Steven M
authors.initials: SM
authors.lastname: Haffner
authors.forename: Mark A
authors.initials: MA
authors.lastname: Heise
authors.forename: William H
authors.initials: WH
authors.lastname: Herman
authors.forename: Rury R
authors.initials: RR
authors.lastname: Holman
authors.forename: Nigel P
authors.initials: NP
authors.lastname: Jones
authors.forename: Barbara G
authors.initials: BG
authors.lastname: Kravitz
authors.forename: John M
authors.initials: JM
authors.lastname: Lachin
authors.forename: M Colleen
authors.initials: MC
authors.lastname: O'Neill
authors.forename: Bernard
authors.initials: B
authors.lastname: Zinman
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Viberti
mesh_terms: D002318:Cardiovascular Diseases / Q000453:epidemiology; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D005905:Glyburide / Q000009:adverse effects / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D008297:Male; D008687:Metformin / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D016016:Proportional Hazards Models; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D049629:Waist-Hip Ratio; D015430:Weight Gain / Q000187:drug effects
chemical_list: D008078:Cholesterol, LDL; D005905:Glyburide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D008687:Metformin; D000077154:Rosiglitazone; D045162:Thiazolidinediones